๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanchang
Clinical trial register · China

Clinical Trials in Nanchang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital of Nanchang University32 AbbVie15 The First Affiliated Hospital of Nanchang University14 Sun Yat-sen University12 Jiangxi Provincial Cancer Hospital12
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Nanchang

432 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
NCT07208058Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
DrugPlonmarlimab
TJ Biopharma Co., Ltd.
Phase 3
30
Beijing, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Nanchang, Shenyang
2025-11-21
Recruiting
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
NCT07241793Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent
DrugsTrastuzumab Rezetecan·Adebrelimab
Sun Yat-sen University
Phase 2
96
Guangzhou, Wuhan, Nanchang, Kunming
2025-11-20
Recruiting
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
DrugGKL-006
Beijing Gene Key Life Technology Co., Ltd
Phase 2
48
Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou
2025-11-14
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
NCT07121413Idiopathic Pulmonary Fibrosis(IPF)
DrugSV001
Shanghai Synvida Biotechnology Co.,Ltd.
Phase 2
48
Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin
2025-11-04
Recruiting
IBI351 Plus Cetuximab ฮฒ in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT07198841Lung Cancer (Non-Small Cell)
DrugPemetrexed
Guangdong Association of Clinical Trials
Phase 2
48
Guangzhou, Beijing, Foshan, Nanchang, Nanning, Shijiazhuang
2025-11-03
Recruiting
Evaluation of the Safety and Effectiveness of CHORDSยฎ Cerebral Protection System During TAVR: DUET Trial
NCT07648693Transcatheter Aortic Valve Replacement (TAVR), Cerebral Vascular Accident (CVA)/Stroke
Resonova (Shanghai) Medtech Limited
Not applicable
240
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanchang, Qingdao
2025-10-31
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751Breast Neoplasms
DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin
BioNTech SE
Phase 3
558
Changde, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing, Neijiang
2025-10-30
Recruiting
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
NCT07569653Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
WeiShi
Phase 4
120
Beijing, Shijiazhuang, Zhengzhou, Jingzhou, Wuhan, Hohhot, Nanchang, Wenzhou
2025-10-30
Recruiting
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
NCT07641634Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic, Scleroderma
Prolium Bioscience, Inc
Phase 1/2
44
Beijing, Guangzhou, Nanchang, Nanjing, Pingxiang
2025-10-27
Recruiting
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
NCT07296705Muscle Invasive Bladder Cancer (MIBC)
DrugsZanidatamab·Nab-paclitaxel·Gemcitabine·Cisplatin
Fujian Medical University Union Hospital
Phase 2
25
Fuzhou, Putian, Quanzhou, Sanming, Xiamen, Zhangzhou, Nanchang, Jinan
2025-10-25
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Nanchang, Beijing, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nantong
2025-10-24
Active, closed
ClinicAL outComes of IntraVascular Lithotripsy Combined With Conventional Lesion Preparation in Patients With Moderate to Severe Coronary Artery Calcification
NCT07340294Coronary Artery Calcification, Calcific Coronary Arteriosclerosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,096
Nanchang, Shenyang, Hangzhou, Tianjin
2025-10-24
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai
2025-10-22
Recruiting
Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window
NCT06987305Stroke, Acute Ischemic
Xinqiao Hospital of Chongqing
Phase 3
820
Wuhan, Xiangtan, Jiujiang, Nanchang
2025-10-21
Recruiting
PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
NCT07775820Lung Cancer, Rechallenge, Checkpoint Inhibitor Pneumonitis
Nanfang Hospital, Southern Medical University
Observational
150
Guangzhou, Shenzhen, Nanchang, Wenzhou
2025-10-20
Recruiting
Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma
NCT07324707Bronchial Asthma
DrugPA9159 Metered- , per day for 28 days
Anhui Palo Alto Pharmaceuticals, Inc.
Phase 2
30
Nanchang
2025-10-15
Recruiting
Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)
NCT07277764Nasopharyngeal Carcinoma (NPC), Recurrent Nasopharyngeal Neoplasms
Jiangxi Provincial Cancer Hospital
Phase 2
23
Nanchang
2025-10-10
Recruiting
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628Acute Coronary Syndrome
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
300
Beijing, Guangzhou, Luoyang, Xuzhou, Nanchang, Wenzhou, Fuzhou, Jining
2025-10-03
Recruiting
Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia
NCT07298824Myopia Progressing
Second Affiliated Hospital of Nanchang University
Phase 2
164
Nanchang
2025-10-01
Recruiting
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
NCT07185373Primary Central Nervous System Lymphoma
DrugsMTX·Orelabrutinib·Rituximab·Dexamethasone
Huashan Hospital
Phase 2/3
215
Beijing, Chengdu, Fuzhou, Guangzhou, Jinan, Nanchang, Nanjing, Shanghai
2025-10-01
Active, closed
Ultrasound Large-scale Model in Thyroid Field: A Multi-center Study on Medical-Engineering Integration
NCT07296575Thyroid Abnormalities, Thyroid, Thyroid Cancer
Second Affiliated Hospital of Nanchang University
Observational
2,000
Nanchang
2025-10-01
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT07022483Endometrial Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
Tianjin Medical University Second Hospital
Not applicable
196
Nanchang, Guangzhou, Xingtai, Kunming, Shanghai, Tianjin
2025-09-28
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07180212Bladder Cancer, Liquid Biopsy, Cystoscopy
Tianjin Medical University Second Hospital
Not applicable
360
Xingtai, Guangzhou, Haerbin, Kunming, Nanchang, Tianjin
2025-09-20
Recruiting
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
NCT07172204Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age โ‰ฅ60
First Affiliated Hospital of Zhejiang University
Phase 2
25
Beijing, Shenzhen, Suzhou, Nanchang, Hangzhou
2025-09-16
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Luoyang, Macau, Nanchang, Shanghai
2025-09-13
Recruiting
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT07174908Non-Small Cell Lung Cancer
InxMed (Shanghai) Co., Ltd.
Phase 3
400
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang
2025-09-10
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
DrugsIzalontamab Brengitecan·BMS-986504
Bristol-Myers Squibb
Phase 2
182
Beijing, Xiamen, Nanning, Nanchang, Jinan, Linyi, Hangzhou, Linhai
2025-09-09
Recruiting
TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease
NCT07295938Mycobacterium Abscessus Pulmonary Disease
Shanghai University of Traditional Chinese Medicine
Phase 2
352
Beijing, Guangdong, Hefei, Nanchang, Shanghai
2025-09-08
Recruiting
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07288554Chronic Obstructive Pulmonary Disease (COPD)
DrugBBT002
Bambusa Therapeutics
Phase 1
68
Hefei, Guangzhou, Jiangmen, Qingyuan, Xinxiang, Yichang, Xuzhou, Nanchang
2025-09-05
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663Systemic Lupus Erythematosus (SLE)
DrugCizutamig
Candid Therapeutics
Phase 1
47
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-09-04
Recruiting
A Randomized Controlled Trial of Combined Bu Shen Yi Qi Decoction and Dehydroepiandrosterone (DHEA) for the Treatment of Ovarian Function Decline
NCT07535983Diminished Ovarian Reserve
Jiangxi University of Traditional Chinese Medicine
Phase 1/2
74
Nanchang
2025-09-01
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
210
Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou
2025-09-01
Not yet open
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
NCT07126288Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD), Growth Hormone
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 2/3
268
Xiamen, Nanyang, Xinxiang, Wuhan, Suzhou, Nanchang, Pingxiang, Changchun
2025-08-31
Recruiting
A Study of SKB518 in Patients With Lung Cancer
NCT07019675Lung Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
192
Shenzhen, Nanning, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanchang, Jinan
2025-08-29
Recruiting
LineMatrixยฎ Biological Vascular Graft for the Creation of Arteriovenous Graft
NCT07773051Arteriovenous Graft
Longhua Hospital
Not applicable
326
Beijing, Chongqing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nanchang
2025-08-25
Recruiting
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706Non-small Cell Lung Cancer (NSCLC)
DrugTaletrectinib
Nuvation Bio Inc.
Phase 3
180
Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Nantong, Nanchang
2025-08-21
Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
NCT07086976Autoimmune Haemolytic Anaemia
DrugRilzabrutinib
Sanofi
Phase 3
90
Beijing, Chengde, Guangzhou, Hohhot, Nanchang, Suzhou, Tianjin, Wuhan
2025-08-18
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
150
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-08-14
Recruiting
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
NCT07239947Atopic Dermatitis
DrugBBT001
Bambusa Therapeutics
Phase 1
99
Hefei, Wuhu, Beijing, Guangzhou, Changsha, Wuxi, Zhenjiang, Nanchang
2025-08-09
Recruiting
Interventional Left Ventricular Assist System for PCI in CHIP Patients
NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
286
Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang
2025-08-06
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
NCT07038382Membranous Nephropathy, Lupus Nephritis (LN)
Shanghai Henlius Biotech
Phase 2
24
Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing
2025-08-05
Recruiting
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
NCT07042126Dermatitis, Atopic
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
180
Beijing, Jinhua, Nanchang
2025-08-05
Recruiting
Real World Evidence Study of SYN023 in Children Exposed to Rabies
NCT07327307Rabies Post-exposure Prophylaxis
Synermore Biologics (Suzhou) Co., Ltd.
Observational
232
Beijing, Shenzhen, Changsha, Hengyang, Nanchang
2025-08-02
Active, closed
3D-Printed Grafts for Knee Cartilage Repair
NCT07312175Osteochondral Lesions of Knee, Osteo Arthritis
Second Affiliated Hospital of Nanchang University
Not applicable
60
Nanchang
2025-08-01
Recruiting
A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies
NCT07113925Advanced Hematologic Malignancies
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
114
Zhengzhou, Nanchang, Shanghai
2025-08-01
Not yet open
Safety Evaluation of Pueraria Lobata Radix in Specific Consumption Scenarios for Type 2 Diabetes
NCT07079085Type 2 Diabetes
Jiangxi University of Traditional Chinese Medicine
Observational
500
Nanchang
2025-08-01
Recruiting
Safety and Efficacy of Platelet-Rich Plasma Combined With Compound Betamethasone in Arthroscopic Surgery for Rotator Cuff Injury With Shoulder Adhesion: A Prospective, Multicenter, Randomized Controlled Trial
NCT07348016Rotator Cuff Injuries, Adhesions
DrugsCompound betamethasone·Liposomal bupivacaine
Second Affiliated Hospital of Nanchang University
Not applicable
70
Nanchang
2025-08-01
Recruiting
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis
NCT07172035Cirrhosis, Decompensation, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Survival Analysis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
250
Changsha, Fuzhou, Huanggang, Jingzhou, Nanchang, Nanjing, Shenyang, Taiyuan
2025-08-01
Recruiting
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
NCT06780111Esophageal Squamous Cell Carcinoma
DrugsLevoleucovorin·Ifinatamab Deruxtecan·Leucovorin·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 1/2
298
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Nanchang
2025-07-30
Not yet open
Investigation on the Prevalence and Etiology of Adolescent Idiopathic Scoliosis in Nanchang Region
NCT06802653Scoliosis Idiopathic Adolescent
Nanchang University Affiliated Rehabilitation Hospital
Observational
400
Nanchang
2025-07-28
Recruiting
Short-term Bactericidal Effect of Contezolid in MAC-PD
NCT07084402Mycobacterium Avium Complex Pulmonary Disease
DrugsContezolid·Ethambutol·Rifampicin
Bin Cao
Phase 4
188
Beijing, Nanchang
2025-07-24
Recruiting
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT06807268Eczema
DrugAbrocitinib
Pfizer
Phase 3
150
Beijing, Shenzhen, Changsha, Nanchang, Shanghai, Hangzhou
2025-07-24
Recruiting
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
NCT07213765Mycobacterium Avium Complex Pulmonary Disease
Bin Cao
Phase 4
188
Hefei, Beijing, Guangzhou, Nanchang, Shanghai
2025-07-24
Recruiting
Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease
NCT07174076Mycobacterium Avium Complex Pulmonary Disease
Bin Cao
Phase 4
300
Hefei, Beijing, Guangzhou, Nanchang, Shanghai
2025-07-24
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
NCT06824168Acute Myeloid Leukemia, Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 2
130
Beijing, Changchun, Guangzhou, Hangzhou, Nanchang, Nanjing, Nanning, Qingdao
2025-07-18
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
NCT07483450Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Phase 4
60
Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot
2025-07-04
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762Advanced Solid Tumor
DrugBevacizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
Diagnostic Performance of an AI-based Model for TCM Constitution Classification Using Ophthalmic Imaging
NCT07127939Ophthalmic Imaging, Deep Learning, Artificial Intelligence (AI), Traditional Chinese Medicine Constitution
Second Affiliated Hospital of Nanchang University
Observational
1,024
Nanchang
2025-07-01
Recruiting
Predictive Performance of a Generative Model for Corneal Tomography After ICL Implantation
NCT07146737ICL, Vault, Deep Learning, AI (Artificial Intelligence)
Second Affiliated Hospital of Nanchang University
Observational
818
Nanchang
2025-07-01
By invitation
Research on the Development and Implementation of an Exercise Rehabilitation Program for Aortic Dissection Patients After Percutaneous Intervention Based on the Behavior Change Wheel Theory
NCT07117500Aortic Dissection
Shuzhen Wang
Not applicable
80
Nanchang
2025-07-01
By invitation
Study on the Efficacy of Non-invasive Spinal Cord Electrical Stimulation in Neuropathic Pain
NCT07046143Neuropathic Pain
Nanchang University Affiliated Rehabilitation Hospital
Not applicable
62
Nanchang
2025-06-25
Recruiting
Research on Binaural Synchronous Vagus Nerve Regulation of Sensorimotor Disorders After Cerebral Infarction
NCT07081568Cerebral Infarction
Nanchang University Affiliated Rehabilitation Hospital
Not applicable
40
Nanchang
2025-06-25
Recruiting
SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors
NCT06936748Cancer
Second Affiliated Hospital of Nanchang University
Phase 2
30
Nanchang
2025-06-20
Recruiting
The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
NCT06995118Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Du Zhenggui
Not applicable
337
Fuzhou, Guangzhou, Anyang, Zhengzhou, Changsha, Hohhot, Suzhou, Nanchang
2025-06-17
Active, closed
A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
NCT07009457Widespread Small Cell Lung Cancer
DrugsEtoposide·Adebrelimab·Carboplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
24
Nanchang
2025-06-16
Recruiting
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
NCT06931691Paroxysmal Nocturnal Hemoglobinuria
DrugIptacopan
Novartis Pharmaceuticals
Observational
80
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun
2025-06-10
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536Crohn's Disease
DrugSAR442970
Sanofi
Phase 2
99
Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang
2025-06-03
Recruiting
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
NCT06954467Hepatocellular Carcinoma
DrugsJS007·JS207
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors
NCT06943677Advanced Malignant Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
80
Beijing, Guangzhou, Zhengzhou, Nanjing, Nanchang, Xi'an, Heze, Jinan
2025-05-26
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581Asthma
DrugPF-07275315
Pfizer
Phase 2
252
Beijing, Guangzhou, Baotou, Hohhot, Najing, Nanjing, Xuzhou, Nanchang
2025-05-20
Recruiting
Research on the Application of Nursing Intervention Based on ITHBC Theory in Postoperative Self-Management of Patients With Varicose Veins of the Lower Extremities
NCT07570277Varicose Veins
Second Affiliated Hospital of Nanchang University
Not applicable
104
Nanchang
2025-05-15
Active, closed
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
NCT06934044Multiple Myeloma
DrugsCevostamab·Tocilizumab
Hoffmann-La Roche
Phase 1
20
Guangzhou, Tianjin, Nanchang, Wenzhou, Wuhan
2025-05-13
Recruiting
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
NCT06929299Primary Immune Thrombocytopenia (ITP)
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 1/2
56
Bengbu, Beijing, Tangshan, Zhengzhou, Nanchang, Xiโ€™an, Tianjin
2025-05-12
Recruiting
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
NCT06623136Non-Small Cell Lung Cancer
Elpiscience (Suzhou) Biopharma, Ltd.
Phase 2
40
Beijing, Zhengzhou, Nanchang, Changchun, Jinan, Luoyang, Taiyuan, Taizhou
2025-04-30
Recruiting
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07140328Chronic Obstructive Lung Disease (COLD)
DrugsHSK39004·HSK39004 Dry
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
50
Nanchang
2025-04-24
Recruiting
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
NCT07131319Non-Small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University
Phase 2/3
30
Nanchang
2025-04-21
Recruiting
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
NCT07347171Leukemia, AML, MDS, AML (Acute Myelogenous Leukemia)
Cullgen (Shanghai),Inc
Phase 1
45
Nanchang, Tianjin, Wuhan
2025-04-17
Recruiting
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ยฑ Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
NCT06821503Advanced Pancreatic Cancer
DrugsLM-108·Penpulimab·Gemcitabine Hydrochloride·Paclitaxel
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
72
Beijing, Chongqing, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang
2025-04-11
Active, closed
Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Radical Resection
NCT06934070Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC) Prognosis
Qiang Xu
Observational
287
Nanchang
2025-04-03
Recruiting
Exploratory Study on the Role of Vitamin C in Promoting Health in Middle-Aged and Elderly Adults
NCT06794255Ageing
Peking University Third Hospital
Not applicable
400
Nanchang, Quzhou, Beijing
2025-04-02
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945Alopecia Areata
DrugRitlecitinib
Pfizer
Phase 3
674
Beijing, Chongqing, Guangzhou, Changsha, Nanchang, Shanghai, Chengdu, Kunming
2025-04-01
Recruiting
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
NCT06977893HR+/HER2- Breast Cancer
DrugTislelizumab
First Affiliated Hospital of Zhejiang University
Phase 3
194
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Nantong, Shanghai, รœrรผmqi
2025-03-24
Recruiting
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor
BeOne Medicines
Phase 1
90
Beijing, Nanchang, Shanghai, Taiyuan
2025-03-18
Not yet open
Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial
NCT06848426Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Jiangxi Provincial People's Hopital
Not applicable
100
Nanchang
2025-03-10
Recruiting
Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
NCT06880081Primary Immune Thrombocytopenia (ITP)
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1
12
Guiyang, Nanchang, Jining, Tianjin, Kunming
2025-03-07
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin
AbbVie
Phase 1/2
252
Beijing, Fuzhou, Liuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2025-03-06
Not yet open
Deep Sedation in Catheter Ablation of Atrial Fibrillation
NCT06836999Atrial Fibrillation, Atrial Fibrillation, Paroxysmal or Persistent, Deep Sedations, Conscious Sedation
The First Affiliated Hospital of Dalian Medical University
Not applicable
1,334
Hefei, Guangzhou, Nanjing, Suzhou, Nanchang, Dalian, Qingdao, Shanghai
2025-03-03
Recruiting
Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension
NCT06970509Esophageal Varices, Portal Hypertension
Shanghai Zhongshan Hospital
Observational
1,450
Guangzhou, Nanchang, Shenyang, Jinan, Shanghai
2025-03-01
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
171
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-02-27
Recruiting
Comparative Study on the Safety and Efficacy of Using AccuSafe Transseptal Guidewire Versus Traditional Transseptal Needle for Transseptal Puncture in non-or Free- Guidance
NCT07515040Atrial Fibrillation (AF)
Second Affiliated Hospital of Nanchang University
Not applicable
80
Nanchang
2025-02-26
Recruiting
Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma
NCT07326995Bronchial Asthma
DrugPA9159 Metered- , per day for 28 days
Anhui Palo Alto Pharmaceuticals, Inc.
Phase 2
60
Nanchang
2025-02-24
Recruiting
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
NCT06839105Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
214
Fuzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Nanchang, Changchun
2025-02-21
Recruiting
Clinical Study of Acupuncture Treatment of Knee Osteoarthritis
NCT06805188Osteoarthritis of the Knees, Osteoarthritis (OA) of the Knee, Osteoarthritis
Wu zenan
Not applicable
350
Nanchang
2025-02-15
Not yet open
Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial
NCT06639516Acute Pancreatitis
The First Affiliated Hospital of Nanchang University
Not applicable
60
Nanchang
2025-02-15
Not yet open
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
NCT06845241Relapsed or Refractory Non-Hodgkin Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
68
Fuzhou, Guangzhou, Zhengzhou, Nanchang, Tianjin, Kunming
2025-02
Not yet open
Evaluation of an Artificial Intelligence Model for the Prediction of Human Blastocyst Ploidy Without Invasive Procedures
NCT06762704The Focus is to Validate the Accuracy of a Non-invasive Artificial Intelligence Model for the Prediction of the Human Blastocyst Ploidy, Preimplantation Genetic Testing (PGT)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
1,408
Hefei, Nanjing, Nanchang, Xi'an, Shanghai
2025-02
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005Advanced Metastatic Castration Resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2
84
Beijing, Fuzhou, Foshan, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang
2025-01-23
Recruiting
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
NCT06698796Dermatomyositis, Polymyositis
Pfizer
Phase 3
211
Hefei, Nanchang, Shanghai, Kunming, Beijing
2025-01-22
Rows per page Showing 101–200 of 432
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanchang?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 432 of those studies with a site in Nanchang.

How many clinical trials are recruiting in Nanchang?

272 of the 432 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 57 have not yet opened recruitment, 94 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.